NASDAQ · ELUT
Elutia Inc
$0.81-$0.00 (-0.42%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
Loading market information…
NYSE · IVC · USD
Stock price, dividends, earnings
Quote as of Jan 31, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Invacare Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Invacare Corporation’s forward annual dividend is $0.05 per share, paid quarterly. The forward yield is 7.58% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Invacare Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Invacare Corporation, along with its affiliated entities, stands as a prominent international provider specializing in the design, production, distribution, and global export of medical devices. These products cater to diverse sectors, including home healthcare, retail environments, and long-term care facilities worldwide. Its extensive product portfolio encompasses mobility and seating solutions. These include power wheelchairs sold under the Invacare TDX brand, custom manual wheelchairs bearing the Invacare, Invacare Top End, and Küschall names, and various seating and positioning aids within the Invacare line. Furthermore, specialized custom molded seat modules are offered under the PinDot brand. Beyond mobility, Invacare supplies a range of daily living aids. This category features pressure-relieving overlays and mattress systems, such as the Invacare Softform and microAIR series; safe patient handling equipment like the Birdie, Evo, and ISA brands; and residential and institutional care beds along with their accessories, and certain manual wheelchairs, all primarily under the Invacare label. The company also provides personal care items. Additionally, the firm is a key supplier of respiratory therapy products. Its offerings here include stationary oxygen concentrators (Platinum, Perfecto2), portable oxygen concentrators (Platinum), and the Invacare HomeFill oxygen systems. In addition to manufacturing, Invacare provides essential services such as equipment repair and rentals, alongside external contracting. The company also acts as a distributor for supplementary health products, including heart rate monitors, thermometers, nebulizers, and portable ramps. Invacare distributes its offerings predominantly to home medical equipment providers, reaching them through both retail outlets and online platforms. It also serves residential care operators, dealers, and government health service customers, leveraging its internal sales teams, independent representatives, and a network of distributors. Established in 1885, Invacare Corporation maintains its headquarters in Elyria, Ohio.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| -$0.12+36.84% vs estimate |
| $224.20M-5.01% vs estimate |
| Q2 2021 | Aug 4, 2021 | -$0.28-21.74% vs estimate | $225.86M+5.25% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.81-$0.00 (-0.42%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
$6.49+$0.01 (+0.15%)
Freeline Therapeutics Holdings plc’s quoted price sits in the upper half of its reported 52-week range, 25.79% below the high.
$4.30-$0.14 (-3.15%)
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$0.29-$0.06 (-17.87%)
Akumin Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.81% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$5.33$0.00 (0.0%)
Streamline Health Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.56% below the high.
$0.21+$0.01 (+5.66%)
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 91.37% below the high.
